Communiqués

Release
16.04.2020

VALBIOTIS accelerates the clinical development of its pipeline in new indications: reducing cardiovascular risk and hepatic steatosis

Download
Release
07.04.2020

VALBIOTIS announces its 2020 financial communication calendar (in French)

Download
Release
02.04.2020

As part of a global partnership with Nestlé Health Science, VALBIOTIS initiates the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits in people with prediabetes

Download
Release
05.02.2020

Corporate Press Kit

Download
Release
05.02.2020

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits on prediabetics

Download
Release
04.02.2020

Suspension of the trading of VALBIOTIS shares on Euronext Growth (in French)

Download
Release
31.01.2020

Half year report of the liquidity contract – January 2019 (in French)

Download
Release
31.10.2019

VALBIOTIS announces the success of its capital increase with maintenance of the DPS for an amount of 7.2 million euros (in French)

Download
Release
10.10.2019

VALBIOTIS launches a share capital increase with Shareholders’ Preferential Subscription Rights (in French)

Download